Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 5
- Registration Number
- NCT00402883
- Locations
- 🇺🇸
Wellstar Cancer Research, Marietta, Georgia, United States
🇺🇸Oncology Hematology Care, Cincinnati, Ohio, United States
🇺🇸Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Treatment of Head & Neck Cancer With Chemotherapy and Radiation
- Conditions
- Interventions
- First Posted Date
- 2006-10-26
- Last Posted Date
- 2013-02-22
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT00392704
- Locations
- 🇺🇸
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
🇺🇸Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-10-26
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 29
- Registration Number
- NCT00392392
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Florida Hospital Cancer Institute, Orlando, Florida, United States
Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-10-26
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 62
- Registration Number
- NCT00393068
- Locations
- 🇺🇸
Northeast Georgia Medical Center, Gainesville, Georgia, United States
🇺🇸Oncology Hematology Care, Cincinnati, Ohio, United States
🇺🇸Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer
- First Posted Date
- 2006-10-26
- Last Posted Date
- 2022-06-06
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 78
- Registration Number
- NCT00392821
- Locations
- 🇺🇸
Norton Cancer Institute, Louisville, Kentucky, United States
🇺🇸Baptist Hospital East, Louisville, Kentucky, United States
🇺🇸Wellstar Cancer Research, Marietta, Georgia, United States
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-10-20
- Last Posted Date
- 2014-12-22
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 85
- Registration Number
- NCT00390611
- Locations
- 🇺🇸
Northeast Arkansas Clinic, Jonesboro, Arkansas, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Holy Cross Hospital, Ft. Lauderdale, Florida, United States
Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site
- Conditions
- Interventions
- First Posted Date
- 2006-08-04
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT00360360
- Locations
- 🇺🇸
Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States
🇺🇸Graves-Gilbert Clinic, Bowling Green, Kentucky, United States
🇺🇸Oncology Hematology Associates of SW Indiana, Evansville, Indiana, United States
Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma
- First Posted Date
- 2006-05-09
- Last Posted Date
- 2013-07-26
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 80
- Registration Number
- NCT00323739
- Locations
- 🇺🇸
Baton Rouge General Medical Center, Baton Rouge, Louisiana, United States
🇺🇸Oncology Hematology Care, Cincinnati, Ohio, United States
🇺🇸Wellstar Cancer Research, Marietta, Georgia, United States
Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies
- Conditions
- First Posted Date
- 2006-04-19
- Last Posted Date
- 2009-01-23
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 15
- Registration Number
- NCT00315861
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2006-03-29
- Last Posted Date
- 2010-06-22
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 55
- Registration Number
- NCT00308529
- Locations
- 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Oncology Hematology Care, Cincinnati, Ohio, United States
🇺🇸Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States